PD-L1 expression measured by immunohistochemistry helps identify non-small cell lung cancer (NSCLC) patients that may respond to anti-PD-1/PD-L1 immunotherapies.
ACHL, Pro-ficiency, Simumetrix and ArcheMedX were recognized for collaboration on The Evolution of Therapies for NSCLC: Navigating New Therapies & Counseling Patients in Clinical Decisions
Pilot programs demonstrate that digital learning increases physician engagement and empowers patients to self-advocate